Preventing Opioid Deaths due to COVID Related Increase in Smoking Illicit Substances (Preventing OD CRISIS)

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:24 publications

Grant number: 173085

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $153,000
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Jessica Moe
  • Research Location

    Canada
  • Lead Research Institution

    B.C. Centre for Disease Control
  • Research Priority Alignment

    N/A
  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    Indirect health impacts

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Drug users

  • Occupations of Interest

    Unspecified

Abstract

During the COVID-19 pandemic, British Columbia (BC) has seen a tragic increase in drug overdose deaths, due to a toxic drug supply, people using drugs alone and difficulty accessing harm reduction services. Overdose prevention services (OPS), where people can use drugs in an observed setting, have struggled to meet physical distancing rules, and visits to OPS sites have fallen by 35% since COVID-19 began. At the same time as this recent spike in fatal overdoses, more people have been dying from smoking drugs in BC since 2016. Many people think that their risk of having an overdose is lower if they smoke opioids than if they inject, but this is not actually true. Also, it is more difficult for people who smoke drugs to use OPS, because many sites do not allow smoking, or if they do, have smoking areas outside that are hard for staff to monitor. During COVID-19, there has been a greater drop in people coming to OPS to smoke drugs than to use drugs in other ways, in part because OPS are not set up well to meet the needs of people who smoke. This study will introduce continuous oxygen monitoring at partnering OPS for people who come to smoke opioids or "down." We will train peer researchers at these sites to enroll participants, and to gather information from them. While smoking opioids, participants will attach a wrist monitor that will read and transmit their oxygen levels to iPads available to OPS staff. We will train OPS staff to check on participants if their low oxygen levels trigger an alarm. We will examine whether people who smoke drugs and OPS staff find our continuous oxygen monitoring protocol useful. We will also look at how and when oxygen levels change when people smoke opioids. We will use our findings to develop harm reduction messaging for people who smoke drugs, to expand monitoring to other OPS and private locations like supportive housing across BC, and to develop oxygen monitoring apps that allow people who use drugs alone to do so more safely.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Conserved requirement of autophagy-related effectors during coronavirus replication.

A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets.

Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta).

Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation.

Replication and single-cycle delivery of SARS-CoV-2 replicons.

Disparate temperature-dependent virus-host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium.

Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome.

Convergent use of phosphatidic acid for Hepatitis C virus and SARS-CoV-2 replication organelle formation

A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets